- Home
- GHM vs SION Comparison
GHM vs SION Comparison
Compare GHM & SION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHM
- SION
- Stock Information
- Founded
- GHM 1936
- SION 2019
- Country
- GHM United States
- SION United States
- Employees
- GHM N/A
- SION N/A
- Industry
- GHM Industrial Machinery/Components
- SION
- Sector
- GHM Industrials
- SION
- Exchange
- GHM Nasdaq
- SION NYSE
- Market Cap
- GHM 336.7M
- SION 338.0M
- IPO Year
- GHM N/A
- SION 2025
- Fundamental
- Price
- GHM $34.88
- SION $12.32
- Analyst Decision
- GHM Buy
- SION Strong Buy
- Analyst Count
- GHM 1
- SION 1
- Target Price
- GHM $35.00
- SION $32.00
- AVG Volume (30 Days)
- GHM 51.7K
- SION 129.2K
- Earning Date
- GHM 06-06-2025
- SION 05-25-2025
- Dividend Yield
- GHM N/A
- SION N/A
- EPS Growth
- GHM 230.32
- SION N/A
- EPS
- GHM 0.83
- SION N/A
- Revenue
- GHM $199,621,000.00
- SION N/A
- Revenue This Year
- GHM $12.25
- SION N/A
- Revenue Next Year
- GHM $9.41
- SION N/A
- P/E Ratio
- GHM $42.02
- SION N/A
- Revenue Growth
- GHM 11.22
- SION N/A
- 52 Week Low
- GHM $24.78
- SION $7.26
- 52 Week High
- GHM $52.00
- SION $25.19
- Technical
- Relative Strength Index (RSI)
- GHM 67.56
- SION N/A
- Support Level
- GHM $31.93
- SION N/A
- Resistance Level
- GHM $33.43
- SION N/A
- Average True Range (ATR)
- GHM 1.41
- SION 0.00
- MACD
- GHM 0.56
- SION 0.00
- Stochastic Oscillator
- GHM 89.83
- SION 0.00
About GHM Graham Corporation
Graham Corporation designs and manufactures mission-critical fluid, power, heat transfer, and vacuum technologies for the defense, space, energy, and process industries. The company also services and sells spare parts for its equipment. It designs and manufactures custom-engineered vacuum, heat transfer, cryogenic pump and turbomachinery technologies.
About SION SIONNA THERAPEUTICS INC
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.